Ongoing and Future Directions in the Management of Metastatic Colorectal Cancer: Update on Clinical Trials

Overview

Journal J Surg Oncol

Specialties General Surgery
Oncology

Date 2019 Mar 11

PMID 30852840

Citations 22

Authors

Shailesh Advani

Scott Kopetz

Affiliations

Soon will be listed here.

Abstract

Metastatic colorectal cancer (mCRC) continues to show poor outcomes, with many patients exhausting effective standard-of-care therapy. To explore the current landscape of clinical trials for mCRC, we reviewed over 600 clinical trials that are currently ongoing for mCRC patients. Immunotherapeutic agents form approximately 39% (includes monoclonal antibodies, viruses, vaccines, and immunomodulators) of all agents and targeted therapy forms 45% (tyrosine kinase inhibitors, epigenetic modulators, and others) of all agents being investigated for mCRC.

Citing Articles

Exosomes and their distinct integrins transfer the characteristics of oxaliplatin- and 5-FU-resistant behaviors in colorectal cancer cells.

Vakili-Ghartavol Z, Deli H, Shadboorestan A, Sahebnasagh R, Motevaseli E, Ghahremani M Mol Med. 2025; 31(1):49.

PMID: 39915745 PMC: 11803997. DOI: 10.1186/s10020-025-01110-y.

ONC206, an imipridone derivative, demonstrates anti-colorectal cancer activity against stem/progenitor cells in 3D cell cultures and in patient-derived organoids.

Monzer A, Ghamlouche F, Wakimian K, Ballout F, Al Bitar S, Yehya A Pharmacol Rep. 2024; 77(1):229-246.

PMID: 39551911 DOI: 10.1007/s43440-024-00676-4.

The METTL3/TRAP1 axis as a key regulator of 5-fluorouracil chemosensitivity in colorectal cancer.

Kang Q, Hu X, Chen Z, Liang X, Xiang S, Wang Z Mol Cell Biochem. 2024; 480(3):1865-1889.

PMID: 39287889 PMC: 11842504. DOI: 10.1007/s11010-024-05116-8.

Ascending colon cancer metastasized to the right testicle: a case report.

Gao Q, Li Y, Zhu L J Med Case Rep. 2024; 18(1):305.

PMID: 38926771 PMC: 11210146. DOI: 10.1186/s13256-024-04587-z.

Immunotherapies targeting tumor vasculature: challenges and opportunities.

Dianat-Moghadam H, Nedaeinia R, Keshavarz M, Azizi M, Kazemi M, Salehi R Front Immunol. 2023; 14:1226360.

PMID: 37727791 PMC: 10506263. DOI: 10.3389/fimmu.2023.1226360.